The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of PLM-102, a novel dual inhibitor of FLT3 and RET as a new therapeutic option for acute myeloid leukemia.
 
Myungjin Kim
No Relationships to Disclose
 
Su-jin Oh
No Relationships to Disclose
 
WooChan Kim
No Relationships to Disclose
 
Yong June Choi
No Relationships to Disclose
 
Jae-Seon Lee
No Relationships to Disclose
 
So-Deok Lee
No Relationships to Disclose
 
Jin-Hee Park
No Relationships to Disclose
 
Eun Ji Lee
No Relationships to Disclose
 
Keon Wook Kang
Stock and Other Ownership Interests - Pelemed
Consulting or Advisory Role - Korea United Pharm
Research Funding - Pelemed
Patents, Royalties, Other Intellectual Property - Compound identification for Immunooncology target
 
Soo Yeon Jang
No Relationships to Disclose
 
Yong-Chul Kim
Leadership - Pelemed
Stock and Other Ownership Interests - Pelemed; Pelemed
Patents, Royalties, Other Intellectual Property - Holding more than 30 registered patents. Performances of technology transfer by licensing out of intellectual properties